J&J wagers on next cell therapy frontier with $2.6bn Sail Bio acquisition option

2026-07-30T10:23:00

J&J logo

Source:

In vivo-focused collaboration has scope to considerably boost therapeutic innovation and address unmet need in immune-mediated diseases.

Janssen Biotech, a Johnson & Johnson (J&J) company and US biotechnology firm Sail Biomedicines have agreed to collaborate to advance innovative in vivo CAR-T therapies for immune-mediated diseases.

With the deal set to strengthen its position in immunology, J&J will pay a total of…

Already a member? Sign-in

Unlock

Driving innovation in pharma manufacturing

European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.

Become a member to continue reading

By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:

  • Unlimited access to industry intelligence that can make a difference to your business
  • A weekly newsletter keeping the most vital information at the front of your thinking
  • Exclusive invitations to powerful webinars and events featuring high profile experts
  • Access to deep-dive reports and analysis that reveal exciting new opportunities for business growth and transformation

Become a member